← Oncology Approval Tracker

FDA DECISION ·

Anktiva + BCG

nogapendekin alfa inbakicept-pmln with BCG · Altor BioScience

FDA approvalNew therapyBladder cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with BCG-unresponsive non-muscle-invasive bladder cancer and carcinoma in situ, with or without papillary tumors; use with intravesical BCG.

LAMPGEN ANALYSIS

Why it matters

The cytokine-based combination provides a bladder-directed option in the defined BCG-unresponsive setting.

What research teams should watch

Reconstruct BCG treatment adequacy and recurrence timing, and plan repeat cystoscopy and urine cytology.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

BCG-unresponsive non-muscle-invasive bladder cancer

PRIMARY RECORDS

Sources